GSK PLC Stock Price, News & Analysis

The pandemic has significantly affected vaccination rates in the U.S., as reported by GSK. From January 2020 to July 2021, teens and adults missed an estimated 37.1 million doses of CDC-recommended vaccines, with monthly claims down 32% for adults and 36% for adolescents compared to 2019. This decline raises concerns over potential public health crises due to lower vaccination rates. GSK emphasizes the importance of increasing vaccine uptake to prevent future health risks.

908 Devices (NASDAQ: MASS) announced that GlaxoSmithKline (NYSE: GSK) has acquired an additional REBEL™ cell culture media analyzer, bringing GSK's total to five units. This device aids in optimizing cell cultures rapidly and is compatible with bioreactor setups. 908 Devices reported that there are now 15 customers with multiple REBEL devices, a significant increase year-over-year. All top 20 pharmaceutical companies are utilizing 908 Devices' products, enhancing their development processes.

ViiV Healthcare has received FDA approval for Apretude, a long-acting injectable HIV pre-exposure prophylaxis (PrEP), the first of its kind to show superior efficacy compared to daily oral options. It is indicated for adults and adolescents over 35 kg at risk of HIV. Apretude can be administered as few as six times a year, with studies showing a 69% to 90% lower incidence of HIV compared to daily oral options. This innovative treatment addresses the needs of vulnerable populations, particularly in Black and Latinx communities, providing an alternative to daily pills.

ViiV Healthcare has released survey data for World AIDS Day, revealing significant stigma and misinformation about HIV. Conducted by The Harris Poll among 5,047 adults in the U.S., UK, Australia, and Portugal, the survey found that 88% of respondents perceive ongoing negative attitudes towards individuals living with HIV. It also highlighted that 76% were unaware that effective treatment can prevent HIV transmission. ViiV emphasizes the need for ongoing anti-stigma campaigns, showcasing collaborative efforts like HIV in View.

Arrowhead Pharmaceuticals (NASDAQ: ARWR) has finalized an exclusive license agreement with GlaxoSmithKline (LSE/NYSE: GSK) for ARO-HSD, a therapeutic for nonalcoholic steatohepatitis (NASH). Arrowhead will receive a $120 million upfront payment and could earn up to $1.1 billion in additional milestone payments and royalties. The agreement allows GSK to develop ARO-HSD globally, except in Greater China, where Arrowhead retains rights. The transaction is expected to close in Q1 2022, pending customary conditions.

On November 17, 2021, GSK's Robitussin announced a partnership with All Stars Project, Inc. to enhance access to performing arts education for underserved youth. Committing $50,000, Robitussin aims to bridge educational inequities highlighted by the National Center for Education Statistics. Additionally, they will collaborate with Tony Award-winning actress Adrienne Warren to elevate young voices. On November 30, an Instagram Live event will further promote the initiative. The company also partnered with Good360 to donate cough care products to those in need, emphasizing its commitment to equitable health solutions.

GlaxoSmithKline (GSK) has announced a partnership with comedian Ronny Chieng for Thanksgiving, offering consumers holiday hacks through TUMS®, the leading heartburn relief brand. From November 23-25, Chieng will answer consumer queries on Twitter, addressing common holiday dilemmas like cooking mishaps. This initiative is part of TUMS®' ongoing efforts to ensure celebratory gatherings are enjoyable despite potential heartburn. TUMS® continues to be the most recommended adult antacid brand, providing quick relief for heartburn and related symptoms.

GlaxoSmithKline plc (GSK) announced positive Phase III results for daprodustat, an oral treatment for anaemia in chronic kidney disease (CKD), at the American Society of Nephrology's Kidney Week 2021. The ASCEND programme, involving over 8,000 patients, demonstrated daprodustat's efficacy and safety, achieving non-inferiority in cardiovascular risk compared to standard treatment. Primary efficacy endpoints were met in both ASCEND-ND and ASCEND-D studies, with improvements in haemoglobin levels. Daprodustat is currently approved in Japan and will support global regulatory filings.

ViiV Healthcare, majority-owned by GSK and partnered with Pfizer, has received approval from the European Commission to update product guidelines for Vocabria and Rekambys. This allows HIV patients the option to start treatment directly with injections, bypassing the oral lead-in phase. The change aims to simplify the treatment initiation process, as both methods have shown similar efficacy and safety. This decision is based on positive phase III clinical trial results that support the new regimen.